Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 61.00K | $ 130.00K | $ 84.68M | $ 10.65M | $ 7.76M |
| Gross Profit | $ 61.00K | $ 130.00K | $ 84.68M | $ 10.65M | $ 7.76M |
| Operating Income | $ -358.75M | $ -247.01M | $ -187.06M | $ -214.78M | $ -211.94M |
| EBITDA | $ -200.64M | $ -226.76M | $ -169.04M | $ -201.15M | $ -215.43M |
| Net Income | $ -342.99M | $ -234.63M | $ -183.12M | $ -250.22M | $ -204.47M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 370.53M | $ 546.22M | $ 640.15M | $ 614.79M | $ 612.62M |
| Total Assets | $ 490.86M | $ 750.03M | $ 937.56M | $ 1.13B | $ 908.28M |
| Total Debt | $ 58.97M | $ 63.17M | $ 67.70M | $ 67.82M | $ 54.57M |
| Net Debt | $ -46.63M | $ -82.48M | $ -55.85M | $ -226.01M | $ -85.83M |
| Total Liabilities | $ 108.03M | $ 95.08M | $ 104.31M | $ 197.62M | $ 189.84M |
| Stockholders' Equity | $ 382.82M | $ 654.95M | $ 833.25M | $ 929.79M | $ 718.44M |
| Cash Flow | |||||
| Free Cash Flow | $ -162.86M | $ -166.38M | $ -193.83M | $ -191.75M | $ -212.35M |
| Operating Cash Flow | $ -162.39M | $ -163.69M | $ -169.56M | $ -126.25M | $ -160.87M |
| Investing Cash Flow | $ 122.42M | $ 184.05M | $ -11.54M | $ -121.57M | $ -273.52M |
| Financing Cash Flow | $ 1.33M | $ 1.74M | $ 10.63M | $ 401.24M | $ 476.79M |
Lyell Immunopharma Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.